[go: up one dir, main page]

PE20090829A1 - Espiroindolinas como moduladores de receptores de quimioquinas - Google Patents

Espiroindolinas como moduladores de receptores de quimioquinas

Info

Publication number
PE20090829A1
PE20090829A1 PE2008001039A PE2008001039A PE20090829A1 PE 20090829 A1 PE20090829 A1 PE 20090829A1 PE 2008001039 A PE2008001039 A PE 2008001039A PE 2008001039 A PE2008001039 A PE 2008001039A PE 20090829 A1 PE20090829 A1 PE 20090829A1
Authority
PE
Peru
Prior art keywords
alkyl
propenoyl
difluorophenyl
indol
piperidinyl
Prior art date
Application number
PE2008001039A
Other languages
English (en)
Inventor
Brian W Budzik
Hilary Schenck Eidam
Ryan Michael Fox
Krista B Goodman
Dimitar B Gotchev
Pamela A Haile
Terry Vincent Hughes
Ronggang Liu
Nathan A Miller
Tamara Ann Miskowski
Clark A Sehon
Andrew Q Viet
Gren Z Wang
Jing Zhang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20090829A1 publication Critical patent/PE20090829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN DERIVADO DE ESPIROINDOLINA DE FORMULA (I), DONDE R1 ES HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, OCF3, ENTRE OTROS; R2 ES H, ALQUILO C1-C4, -CH2C(O)OR9 O CH2C(O)N(R9)2; R3 ES ALQUILO C1-C6 O HIDROXI-ALQUILO C1-C6; R4 ES OH, F, Cl, CN, ALQUILO C1-C4, ENTRE OTROS; Y ES -CH=CH- O NH; R5 ES H, OH, F, CF3, ENTRE OTROS; R6 ES HALOGENO, CF3, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; R7 ES H, ALQUILO C1-C4 O JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS, FORMAN UN GRUPO HETEROCICLOALQUILO DE 5 O 6 MIEMBROS; R10 ES OH, F, Cl, ALQUILO C1-C4, ENTRE OTROS; n ES 0, 1 O 2; m ES UN ENTERO DE 0 A 3; p ES 0, 1 O 2; q ES 0, 1 O 2; s ES 0 O 1. SON COMPUESTOS PREFERIDOS: 2-(6-CLORO-1,2-DIHIDRO-1'H-ESPIRO[INDOL-3,4'-PIPERIDIN]-1'-IL)-1-{1-[(2E)-3-(3,5-DIFLUOROFENIL)-2-PROPENOIL]-4-PIPERIDINIL}ETANOL, 1'-((2R)-2-{1-[(2E)-3(3,5-DIFLUOROFENIL)-2-PROPENOIL]4-HIDROXI-4-PIPERIDINIL}-2-HIDROXIETIL)-1,2-DIHIDROESPIRO[INDOL-3,4'-PIPERIDINA]-6-CARBONITRILO, 1'-((2S)-2-{1-[(2E)-3-(3,5-DIFLUOROFENIL)-2-PROPENOIL]-4-PIPERIDINIL}-2-HIDROXIETIL)-1,2-DIHIDROESPIRO[INDOL-3,4'-PIPERIDINA]-6-CARBONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE RECEPTORES DE QUIMIOQUINAS, PARTICULARMENTE, ANTAGONISTAS DE CCR2, Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS INFLAMATORIOS, ENFERMEDADES AUTOINMUNES, ENTRE OTROS
PE2008001039A 2007-06-20 2008-06-18 Espiroindolinas como moduladores de receptores de quimioquinas PE20090829A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94514707P 2007-06-20 2007-06-20
US4315608P 2008-04-08 2008-04-08

Publications (1)

Publication Number Publication Date
PE20090829A1 true PE20090829A1 (es) 2009-07-25

Family

ID=40137143

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001039A PE20090829A1 (es) 2007-06-20 2008-06-18 Espiroindolinas como moduladores de receptores de quimioquinas

Country Status (9)

Country Link
US (2) US7723350B2 (es)
EP (1) EP2166848A4 (es)
JP (1) JP5341076B2 (es)
AR (1) AR067056A1 (es)
CL (1) CL2008001810A1 (es)
PE (1) PE20090829A1 (es)
TW (1) TW200904423A (es)
UY (1) UY31162A1 (es)
WO (1) WO2008157741A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015708B (zh) * 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
EP2370423A4 (en) * 2008-12-04 2012-05-30 Glaxo Group Ltd PROCESS FOR PREPARING A SPIROINDOLINE AND A PREVENT Therefor
WO2010093578A1 (en) * 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
US8563722B2 (en) 2009-02-24 2013-10-22 Glaxo Group Limited Stereoselective hydrogenation of a ketone
AU2011212478B2 (en) 2010-02-05 2014-11-06 Intervet International B.V. Spiroindoline Compounds For Use as Anthelminthics
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds
US10503774B2 (en) * 2012-01-27 2019-12-10 Koninklijke Philips N.V. Medical selection system
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
EP3570893A1 (en) 2017-01-17 2019-11-27 GlaxoSmithKline Intellectual Property Development Ltd Non peptidic heterobivalent molecules for treating inflammatory diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2278309A1 (en) * 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
GB0107907D0 (en) * 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
WO2004041279A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
CA2546147A1 (en) * 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
EP1802602A1 (en) * 2004-09-28 2007-07-04 Janssen Pharmaceutica N.V. Substituted dipiperdine ccr2 antagonists
CN101227903A (zh) 2005-06-02 2008-07-23 詹森药业有限公司 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物
US20070197590A1 (en) * 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
EP2190286A4 (en) * 2007-08-14 2011-06-01 Glaxo Group Ltd SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS
JP2011500590A (ja) * 2007-10-11 2011-01-06 グラクソ グループ リミテッド ケモカイン受容体のモジュレータとしてのピペリジニルヒドロキシエチルピペリジン誘導体
WO2009061881A1 (en) 2007-11-07 2009-05-14 Glaxo Group Limited Spirodihydrobenzofurans as modulators of chemokine receptors
ES2414159T3 (es) * 2008-06-23 2013-07-18 Janssen Pharmaceutica, N.V. Antagonistas de acrilamida piperidilo de CCR2

Also Published As

Publication number Publication date
EP2166848A4 (en) 2011-08-03
JP5341076B2 (ja) 2013-11-13
US20080318990A1 (en) 2008-12-25
JP2010530886A (ja) 2010-09-16
CL2008001810A1 (es) 2008-12-26
UY31162A1 (es) 2008-11-28
AR067056A1 (es) 2009-09-30
EP2166848A1 (en) 2010-03-31
US20110034499A1 (en) 2011-02-10
WO2008157741A1 (en) 2008-12-24
US7723350B2 (en) 2010-05-25
TW200904423A (en) 2009-02-01
US8431590B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
PE20090829A1 (es) Espiroindolinas como moduladores de receptores de quimioquinas
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20081837A1 (es) Derivados de quinuclinidol como antagonistas de los receptores muscarinicos
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
AR037243A1 (es) Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
PE20231215A1 (es) Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
AR043181A1 (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6
CA2682329A1 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
PE20011166A1 (es) Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina
RU2008126807A (ru) Арил-изоксазол-4-ил-имидазо[1,2-а]пиридин, пригодный для лечения болезни альцгеймера через посредство gaba-рецепторов
NZ590297A (en) 2-Alkylamino-7,8-dihydropteridin-6(5H)-one and 2-alkylamino-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one derivatives
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
MY137609A (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FD Application declared void or lapsed